07.31.13
Allergan
2Q Revenues: $1.6 billion (+11%)
2Q Earnings: $361.2 million (+22%)
YTD Revenues: $3.1 billion (+9%)
YTD Earnings: $375.6 million (earnings were $527.6 million YTD12)
Comments: Specialty pharmaceuticals sales increased 11% to $1.3 billion in the quarter, driven by Botox/Neuromodulator sales (+11% to $513 million) and skin care (+39% to $112.3 million). Medical devices sales increased 7% to $229.3 million.
YTD results include a loss of $251.4 million for discontinued operations.
2Q Revenues: $1.6 billion (+11%)
2Q Earnings: $361.2 million (+22%)
YTD Revenues: $3.1 billion (+9%)
YTD Earnings: $375.6 million (earnings were $527.6 million YTD12)
Comments: Specialty pharmaceuticals sales increased 11% to $1.3 billion in the quarter, driven by Botox/Neuromodulator sales (+11% to $513 million) and skin care (+39% to $112.3 million). Medical devices sales increased 7% to $229.3 million.
YTD results include a loss of $251.4 million for discontinued operations.